US EditionRapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights
Summary by modernretina.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Rapid Improvements In DME With Next-Generation Anti-VEGF Therapies: Case Highlights
Dilsher S. Dhoot, MD discusses how second-generation anti-VEGF agents like aflibercept 8mg and faricimab demonstrate significant efficacy in treating diabetic macular edema (DME), allowing for extended treatment intervals of 9-10 weeks compared to monthly dosing with earlier agents, while improving anatomic outcomes and visual acuity.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage